Carl Zeiss Meditec AG

News Details

Related Party Transactions | 10 September 2021 09:21

Carl Zeiss Meditec AG: Release according to Article 111c of the AktG [the German Stock Corporation Act] with the objective of Europe-wide distribution

Carl Zeiss Meditec AG / Release of an announcement according to Article 111c of the AktG [the German Stock Corporation Act]

10.09.2021 / 09:21

Dissemination of a Related Party Transactions announcement transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG enters into a new trademark license agreement with Carl Zeiss AG
Jena, 10 September 2021 On 10 September 2021, Carl Zeiss Meditec AG, Jena (ISIN: DE0005313704), entered into a new trademark license agreement for the commercial continued use of the ZEISS brand with Carl Zeiss AG, Oberkochen, Germany, as the licensor. Car Zeiss AG directly and indirectly holds a total stake of around 59% in Carl Zeiss Meditec AG. Under this agreement, Carl Zeiss Meditec AG will pay Carl Zeiss AG annual trademark license fees in equivalent to 1.5% of the average revenue of the last five fiscal years preceding the year of the agreement. An initial expense of around €20m is expected for the coming fiscal year 2021/22. The term of the trademark license agreement is three years, starting on 1 October 2021, and will be automatically extended by a further two years unless either party objects to it with a six weeks’ notice at the end of the term. Total trademark license expenses of more than €60m are expected over the three-year period. The agreement replaces an earlier trademark licensing agreement between Carl Zeiss Meditec AG and the ZEISS Group which had the same material terms and conditions. The formula for calculating the trademark license expense remains unchanged compared to the previous agreement. Therefore, the new trademark licensing agreement has no impact on the Company’s financial targets. In the opinion of the Management Board of Carl Zeiss Meditec AG, the terms and conditions of the trademark license agreement continue to be considered as customary in the market, as was the case in the previously concluded trademark license agreement. The Management Board regularly reviews market conformity, taking into account the resources invested by Carl Zeiss AG in the brand image and the services provided to Carl Zeiss Meditec AG.

Carl Zeiss Meditec AG enters into a new trademark license agreement with Carl Zeiss AG

Jena, 10 September 2021

On 10 September 2021, Carl Zeiss Meditec AG, Jena (ISIN: DE0005313704), entered into a new trademark license agreement for the commercial continued use of the ZEISS brand with Carl Zeiss AG, Oberkochen, Germany, as the licensor. Car Zeiss AG directly and indirectly holds a total stake of around 59% in Carl Zeiss Meditec AG.

Under this agreement, Carl Zeiss Meditec AG will pay Carl Zeiss AG annual trademark license fees in equivalent to 1.5% of the average revenue of the last five fiscal years preceding the year of the agreement. An initial expense of around €20m is expected for the coming fiscal year 2021/22. The term of the trademark license agreement is three years, starting on 1 October 2021, and will be automatically extended by a further two years unless either party objects to it with a six weeks’ notice at the end of the term. Total trademark license expenses of more than €60m are expected over the three-year period. The agreement replaces an earlier trademark licensing agreement between Carl Zeiss Meditec AG and the ZEISS Group which had the same material terms and conditions. The formula for calculating the trademark license expense remains unchanged compared to the previous agreement. Therefore, the new trademark licensing agreement has no impact on the Company’s financial targets.

In the opinion of the Management Board of Carl Zeiss Meditec AG, the terms and conditions of the trademark license agreement continue to be considered as customary in the market, as was the case in the previously concluded trademark license agreement. The Management Board regularly reviews market conformity, taking into account the resources invested by Carl Zeiss AG in the brand image and the services provided to Carl Zeiss Meditec AG.

Contact for investors and press

Sebastian Frericks

Head of Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

Email: [email protected]

10.09.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language:	English
Company:	Carl Zeiss Meditec AG
	Göschwitzer Str. 51-52
	07745 Jena, Germany
	Germany
Internet:	www.zeiss.de/meditec-ag/ir



End of News	DGAP News Service

show this

AI Terminal

74_rpt_2021-09-10_9bf08c37-d6da-4bc5-ae13-21d1be81e75c.html

More from Carl Zeiss Meditec AG

Talk to a Data Expert